India, May 27 -- EOM Pharmaceuticals Holdings Inc. (IMUC), a clinical-stage biotechnology company, on Wednesday reported FDA clearance of the investigational new drug (IND) application for EOM613 in treating cancer cachexia, allowing for the initiation of the Phase 2a clinical trial.
Cancer cachexia is a debilitating wasting syndrome experienced by cancer patients on chemotherapy, marked by severe weight and muscle loss, anorexia, anemia, and hypoproteinemia. It is caused by an inflammatory process producing cytokines that degrade proteins, leading to hypermetabolim and muscle wasting. There are no FDA-approved treatments for cancer cachexia.
EOM's lead drug candidate, EOM613, is a peptide nucleic acid-based broad spectrum immune regulati...